Fed. Circ. Won't Protect Bayer From Generic Yasmin

Law360, New York (April 16, 2012, 3:09 PM EDT) -- The Federal Circuit on Monday shut down Bayer Healthcare Pharmaceuticals Inc.’s attempt to block production of a generic version of birth control medication Yasmin, affirming a lower court’s ruling that a group of generic-drug makers did not infringe a Bayer patent.

In a 2-1 decision, the appeals court consolidated and affirmed two New York federal court decisions that dismissed Bayer’s patent infringement suits against Watson Laboratories Inc., Lupin Pharmaceuticals Inc. and Sandoz Inc. over the companies’ plans to market a generic form of Yasmin solely for...
To view the full article, register now.